Remember meForgot password?
    Log in with Twitter
Press Release

Clinical Ink Notches 2015 Milestones and Record Results

WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - March 23, 2016) - Clinical Ink®, the pioneering provider of eSource solutions for clinical trials, today announced financial results for the full year 2015 and noted significant customer achievements.

"We are well positioned for a strong 2016 and beyond with solid sales growth generated by multiple multi-trial deals and a record backlog," said Ed Seguine, Clinical Ink's chief executive officer. "These business results attest to Clinical Ink's unique solution and long-term growth prospects. Our investments in platform capabilities, scale and people are paying off, as more customers recognize the compelling business benefits of abolishing paper and EDC from their clinical research processes to accelerate innovation in drug development."

2015 milestones include:

  • Record full-year revenue, representing a 92% year-over-year increase and the third consecutive year of revenue increases exceeding 90%.
  • Total contract bookings exceeded $37 Million and average contract size grew by 25%.
  • New clients added in 2015 included Top 5 Pharmaceutical companies as well as Global CROs.
  • The SureSource® platform surpassed 6,000 users in 20 countries.
  • The company was ranked at No. 57 on the Inc. 5000 national list of fastest growing companies.
  • Clinical Ink released the results of an eSource site user survey which quantified the business impact of real-time data capture and confirmed that sites are eager to adopt tools that simplify the clinical trial process.
  • Expanded eSource product functionality to include the capture of patient data through the merger with CentrosHealth® and the release of a drug supply accountability module to automate clinical supplies tracking.

"Clinical Ink delivers a truly new operating model for clinical trials of the future, today," said Liz Stoner, MD, Managing Director at MPM Capital and former Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories. "Changing the way source documents and data are captured fundamentally changes the experience for sites and patients. This change represents the most compelling innovation for clinical trial process improvement introduced in the last 20 years. Based on the evidence, companies are embracing this new model and look forward to simplifying the clinical trial experience." 

Capturing patient data electronically in real-time using Clinical Ink's SureSource at clinical trial sites and CentrosHealth for patients, ensures the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission, and delivers benefits that legacy technologies do not. Clinical Ink eliminates the need for EDC and on-site source data verification, allowing for true remote monitoring saving time and money while increasing quality.

About Clinical Ink
Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier -- for sites, sponsors and patients. Clinical Ink's SureSource® and CentrosHealth® solutions directly capture eSource data and documents and improve patient engagement while streamlining clinical development. Clinical Ink maintains offices in Winston-Salem, NC, and Philadelphia, PA. Additional information is available online at

Jim Dorsey
Clinical Ink

Latest News
Top News